Amit Khot
0000-0002-9210-5373
University of Melbourne
51 papers found
Refreshing results…
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Lenalidomide maintenance in Myeloma – a goldilocks problem?
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease
Supplementary Tables S1-S7 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Supplementary Methods from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Data from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Supplementary Figure S3 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Supplementary Figure S1 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Supplementary Figure S2 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Del(1p32): prime time in (ultra) high-risk myeloma
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma
Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial
Enablers and barriers to referral and delivery of multidisciplinary prehabilitation in the Autologous Stem Cell Transplant population: A theory-based interview study
Cytomegalovirus DNAemia and disease: current‐era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation
The development of a home-based therapeutic platform for multiple myeloma
Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre
Missing publications? Search for publications with a matching author name.